


The Parenteral Drug Association presents:

PDA Exchange Series

Meet, Exchange and Connect with Professionals
from Related Fields and Expand your Knowledge!



**TWO
CONFERENCES IN
ONE TICKET!**



11th Workshop on Monoclonal Antibodies

Applications of Prior Knowledge to Monoclonal Antibody
Discovery, Development and Commercialization

Pharmaceutical Freeze Drying Technology

Freeze Drying of the Future



27-28 November 2018

Hotel Meliá Sevilla

Seville | Spain

Welcome
to the beautiful city
of Seville!






SCHEDULE AT A GLANCE

27 November 28 November	11th Workshop on Monoclonal Antibodies	Conference, Exhibition
27 November 28 November	Pharmaceutical Freeze Drying Technology	Conference, Exhibition
27 November	Networking Event	
29 November	Application of a Risk-Based Approach to Freeze-Drying Processes	Training Course
29 November 30 November	Development of a Freeze-Drying Process	Training Course
29 November 30 November	CMC Regulatory Compliance for Biopharmaceuticals	Training Course
29 November 30 November	Extractables & Leachables	Training Course

Welcome to the **11th Workshop on Monoclonal Antibodies**

Applications of Prior Knowledge to
Monoclonal Antibody Discovery,
Development and Commercialization



SCIENTIFIC PLANNING COMMITTEE

Michael De Felippis,

Eli Lilly, Workshop Chair

Martijn van de Plas,

Medicines Evaluation Board, Workshop Chair

Mihaela Buda, *EDQM*

Barry Cherney, *Amgen*

Juan Gimenez, *Genentech / Roche*

Steffen Gross, *Paul-Ehrlich-Institut*

Susanne Joerg, *LONZA*

Lutz Mathe, *GE Healthcare*

Brian Mullan, *Novartis*

Falk Klar, *PDA Europe*

Teresa Schubach, *PDA Europe, Manager Programs & Events*

Dear Colleagues,

We warmly invite you to come join the

**PDA Europe 11th Workshop on Monoclonal Antibodies,
27-28 November in Seville, Spain.**

Three decades after the licensure of the first monoclonal antibody, interest remains strong in this product class.

An estimated 300 compounds are currently in various stages of clinical development for treatment of cancers, inflammatory and autoimmune diseases and other disorders. The intense focus on monoclonal antibodies has in turn driven significant developments in the chemistry, manufacturing and control aspects associated with commercial production. The PDA Workshop offers an overview on all these developments, inviting speakers from the

manufacturing side as well as regulatory experts.

The workshop has been taking place annually since 2007, and it stands out as a highly interactive event with presentations, case studies and panel discussions.

This year, the workshop will once again be part of the **PDA Europe Exchange Series** Format. This means it happens **in parallel to the Pharmaceutical Freeze Drying Conference** held in the same location, offering you the chance to participate in two meetings when you register for either one!

We look forward to welcoming you to beautiful Seville later this Fall for a chance to meet, exchange and connect with old colleagues and new ones!

Sincerely,

The Co-Chairs



Michael de Felippis, PhD.,
Eli Lilly, Workshop Chair



Martijn van de Plas, PhD.,
Medicines Evaluation Board, Workshop Chair

Tuesday, 27 November 2018

9:00 Welcome: Opening Remarks & Introductions

Falk Klar, *PDA Europe*

Michael De Felippis, *Eli Lilly, Workshop Chair*

Martijn van der Plas, *Medicines Evaluation Board, Workshop Chair*

9:15 Keynote: Regulatory Perspective on Prior Knowledge

Martijn van der Plas,
Medicines Evaluation Board

Session 1 Regulatory Updates

*Moderator: **Martijn van der Plas,**
Medicines Evaluation Board*

The regulatory landscape is continuously evolving, and several long-term developments can be discerned (ICH Q12; Reflection paper on comparability and statistics). Importantly, the 2017 EMA workshop on Prior Knowledge has triggered new regulatory thinking in this field. This session will present and summarize some of the important current conversations.

9:45 Microbial Control Strategies in the Manufacturing of Monoclonal Antibodies: Lessons Learned and Moving Forward

Patricia Hughes, *US FDA*

10:15 Regulatory Updates on Biological Medicinal Products

David Pérez Caballero, *AEMPS*

10:45 Coffee Break, Poster Session & Exhibition

11:15 The Case Against Product Monographs for Biotechnology Products

Barry Cherney, *Amgen*

11:45 The European Pharmacopoeia Approach to Monoclonal Antibodies

Emmanuelle Charton, *EDQM*

12:15 Panel Discussion with Regulatory and Industry Representatives

David Pérez Caballero, *AEMPS*
Patricia Hughes, *US FDA*
Emmanuelle Charton, *EDQM*
Mihaela Buda, *EDQM*
Martijn van der Plas, *Medicines Evaluation Board*
Barry Cherney, *Amgen*

12:45 Lunch Break, Poster Session & Exhibition

Session 2 Bioassays – Trends, Development and Expectations

*Moderator: **Mihaela Buda,**
EDQM*

Monoclonal antibodies are structurally complex and may have several functional domains within a single molecule. Assessment of biological activity using various cell-based and binding assays is an essential component of product characterisation and quality control, as well as of the biosimilar comparability exercise. In turn, these bioassays must be reliable and standardised, relevant to reflect the product's mode of action, and sensitive to evaluate impact of process-related heterogeneity on critical product quality attributes and detect structural differences between closely related molecules. This session will include presentations describing bioassay case studies and highlighting perspectives and best practices across the scientific community. These case studies will cover aspects related to bioassay development, choice of reference standards and control of assay performance, as well as to the use of bioassays to characterise the structure-activity relationship. Current initiatives to develop a common cell-based assay for the determination of potency of different TNF-alpha antagonists will be outlined.

13:45	Regulatory Perspective on Bioassays	Mihaela Buda, <i>EDQM</i>
14:15	International Standards for Bioassay Calibration	Sandra Prior, <i>NIBSC</i>
14:45	Stability Indication of Bioassays	Gael Debaue, <i>UCB</i>
15:15	Q&A, Discussion	

15:30 Coffee Break, Poster Session & Exhibition

Session 3 Drug Products, Formulation and Delivery

*Moderator: Susanne Joerg,
LONZA*

Over the last decades, challenges and requirements for biological drug products did evolve significantly. Whereas on the one hand an increasing number of bio-therapeutics that differ from the traditional monoclonal antibody format made their way into clinical studies and onto the market, on the other hand emerging biosimilars are making treatment for severe diseases more affordable. Many new drug products nowadays are developed as products using drug delivery technologies, such as pens, autoinjectors or subcutaneous infusion pumps. Development of these combination products need to consider product compatibility and quality, device functionality as well as regulatory requirements. Another frequent challenge during early drug product development is the requirement for low clinical dosing strategies to enable the regulatory requirements with regards to initial clinical doses for healthy volunteers according to the MABEL approach. Particular dosing strategies need to be put in place and analytical methods need to be established to prove that the product can be delivered to the patient in the right quality and quantity.

16:00	Challenges of Low Dose Administration MABEL Dosing Approaches	Monika Geiger, <i>LONZA</i>
16:30	A QbD Approach to Formulation Robustness	Christine Wurth, <i>Roche</i>
17:00	Innovation Drug Delivery Systems for Biopharmaceuticals	Michael McGowan, <i>SHL Group</i>
17:30	Q&A, Discussion	
18:00	End of Conference Day 1	
18:30	Networking Event	

The Parenteral Drug Association is proud to invite you to a very special Networking Event.

Tuesday, 27 November 2018

18:30h – Meeting Point: Hotel Lobby

Joint Walking Tour and Sightseeing in Seville

19:30h – Dinner, Ristorante „La Raza“, Avda. Isabel the Catholic 2, 41013 Seville

21:00h – Walking Tour back to Conference Hotel



Join us for a fabulous evening in a traditional Spanish Restaurant. Restaurant La Raza: In the park of Maria Luisa, opposite the Casino Exhibition and Teatro Lope de Vega, surrounded by extensive vegetation and several outdoor terraces, is a privileged place in the city that has become a benchmark for an evening out in Seville.

Wednesday, 28 November 2018

9:00 Welcome

Michael De Felippis,
Eli Lilly, Workshop Chair

Martijn van der Plas,
*Medicines Evaluation Board,
Workshop Chair*

Session 4 Process Development and Manufacturing

*Moderator: Brian Mullan,
Novartis*

Following initial identification during process development and characterization of product quality attributes and the role of process parameters that influence these, ongoing knowledge management and process understanding continues in the post-approval/commercial supply phase for biologics products. In this session an overview of current thinking on approaches for continued process development, control strategy evolution and management will be presented, followed by a specific example concerning highly concentrated protein solutions. To close, a perspective on the potential of new technologies and the role they could play in enhancing process understanding and control will be shared, that of “-omics” technologies (understanding of the role of interfering RNAs, and of the host cell proteome, in product quality and process stability).

9:05 A Systematic Approach to Control System Updates of Established Products

Jan Pollmann, *Roche*

9:30 Manufacturing a Therapeutic Fab for High Concentrations - Filtration and Viscosity Challenges

Marc Pompiati, *Roche*

9:55 Application of ‘-Omics’ Technologies in MAbs Manufacturing

Niall Barron, *University College Dublin*

10:20 Q&A, Discussion

10:30 Coffee Break, Poster Session & Exhibition

Session 5 Control Strategies

*Moderator: Michael De Felippis,
Eli Lilly*

Control strategies for monoclonal antibodies have evolved with the experience gained over decades of development, commercialization and regulation of this therapeutic class. The ability to produce a variety of monoclonal antibodies based on a shared molecular architecture but with different specificities has resulted in significant product understanding related to a given manufacturer’s product portfolio. Likewise, the implementation of platform manufacturing processes has enabled manufacturers to acquire extensive process knowledge. All of this accumulated prior knowledge is foundational for the life-cycle management of existing products and applicable to the control strategies for future products. This session explores the application of prior knowledge for developing the control strategies of monoclonal antibody products.

11:00 Use of Prior Knowledge in Establishing Control Strategies

Barbara Rellahan, *Amgen*

11:30 Leveraging the Learnings of 10 Years of Developing Control Strategies Post ICH Q8 Part II

Felix Kepert, *Roche*

12:00 Application of Prior Knowledge to Drug Substance Process Development

Theresa Ahern, *Eli Lilly*

12:30 Q&A, Discussion

13:00 Lunch Break, Poster Session & Exhibition

Session 6 Post-Approval Life Cycle Management

Moderator: **Juan Gimenez,**
Genentech/Roche

In this session, different aspects of the life-cycle management of licensed products will be discussed, including key features of emerging guidelines for managing post-approval changes such as ICH Q12 and the WHO document on procedures and data requirements for changes to approved biopharmaceutical products. Considerations regarding interpretation of the guidelines for product comparability after post-approval changes with respect to quality, safety, and efficacy will be presented. This session will also cover examples of how companies manage legacy products by applying science and risk-based concepts, while leveraging cumulative manufacturing experience, product knowledge, and advances in analytical methods. And how this knowledge and strategies are used to bring process and product controls up to higher standards, meeting current expectations from Health Authorities.

14:00	Can ICH Q12 Unlock Manufacturing Innovation?	Ursula Busse, <i>Novartis</i>
14:25	QRM Application to Biopharma Operations in the Q12 Era	Jose Menezes, <i>4Tune Engineering</i>
14:50	Q&A, Discussion	
15:00	Coffee Break, Poster Session & Exhibition	

Closing Plenary: Biosimilar Variations & Biosimilar Product Development

Moderator: **Steffen Gross,**
Paul-Ehrlich-Institut

Despite the fact that biosimilars are developed based on the information for the reference product, developing and manufacturing as well as the approval of biosimilars remains challenging. A stepwise approach is based on a comprehensive structural and functional comparability assessment of the biosimilar to the reference product. Demonstrating a high level of analytical similarity is the first step. All structural elements and modifications of a protein should be evaluated with full capability of detecting differences. Based on observed characteristics of the reference product, a quality target product profile is defined for a biosimilar. The definition of similarity ranges and the acceptance of certain quality differences are a major challenge during evaluation of MAA. It should be noted that after initial approval the biosimilar products will have their own life cycle. Biosimilar manufacturers may need to make changes or alter their own manufacturing processes to enhance product quality and yield, or increased efficiency and improved reliability of the manufacturing process. As it is currently not foreseen to re-demonstrate biosimilarity to the reference material or even among different biosimilars it will be a major future task for industry as well as for regulatory agencies to maintain continuity of product quality and/or biosimilarity. This session will help exploring how this goal might be achieved.

15:30	Biosimilar Development	Michelle Frazier, <i>Coherus BioScience</i>
15:55	Structure-function Relationships for GP2015/Erelzi	Robert Mayer, <i>Novartis</i>
16:20	Q&A, Discussion	
16:30	End of Conference and Farewell	Michael De Felippis, <i>Eli Lilly, Workshop Chair</i> Martijn van der Plas, <i>Medicines Evaluation Board,</i> <i>Workshop Chair</i> Falk Klar, <i>PDA Europe</i>


2019 PDA EUROPE

Advanced Therapy Medicinal Products



Welcome to **Pharmaceutical Freeze Drying Technology**

Freeze Drying of the Future



SCIENTIFIC PLANNING COMMITTEE

Yves Mayeresse, *GSK Vaccines, Chair*

Sascha Pfeiffer, *Lyo Engineering, Co-Chair*

Thomas Beutler, *GEA Lyophil*

Raf de Dier, *Janssen J&J*

Julian Gitter, *University of Munich*

Joerg Luemkemann, *F. Hoffmann - La Roche*

Ingo Presser, *Boehringer-Ingelheim*

Jochen Strube, *University of Clausthal-Zellerfeld*

Kerstin Wilken, *PDA Europe*

Sylvia Becker, *PDA Europe, Manager Programs & Events*

Dear Colleague,

We warmly invite you to come join the 2018 conference on **Pharmaceutical Freeze Drying Technology, 27-28 November in Seville, Spain.**

During the last ten years, freeze-drying of biopharmaceuticals has become a routine procedure, yet the freeze-drying process remains complex. This meeting provides updates of various technical and regulatory aspects regarding lyophilization.

Speakers from the pharmaceutical industry, manufacturers and regulatory agencies regularly share their knowl-

edge and give insights into this process, deepening the understanding of the underlying physicochemical principles as well as explaining freeze-drying techniques and the efforts to implement them on a big scale. All attendees learn about current and novel concepts of freeze-drying and get to connect and exchange ideas with experts in the field.

This year, the workshop will be part of the **PDA Europe Exchange Series** Format. This means it happens in parallel to the **11th Workshop on Monoclonal Antibodies** held in the same location, offering you the chance to participate in two meetings when you register for either one!

The friendly yet professional atmosphere of PDA's meetings provides abundant room for questions and answers, networking and exchange.

Come meet with highly qualified and diverse professionals at this must-attend conference on lyophilization in beautiful Seville in November!

Sincerely,

The Co-Chairs



Yves Mayeresse,
GSK Vaccines, Chair



Sascha Pfeiffer,
Lyo Engineering, Co-Chair

Tuesday, 27 November 2018

9:00 Welcome & Introduction

Kerstin Wilken, *PDA Europe*

Yves Mayeresse, *GSK, Chair*

Sascha Pfeiffer,
Lyo Engineering, Co-Chair

OPENING PLENARY

Session 1 Advancements in Process and Product Development

Moderator: Yves Mayeresse, GSK

Sometimes, unexpected developments bring unexpected challenges. So it happened that the F-Gas regulation change in 2015 has had an impact on all the low temperature compressors, and supply shortages in gas have caused a search for new refrigerants. Some solutions will be proposed in a first part of the session, then the focus will be on products. Live virus vaccines have been produced for decades, they were one of the first commercialized freeze-dried products in the pharmaceutical industry. Other polysaccharidic and protein vaccines were subsequently produced, but now the live viruses are coming back as vectors to cure diseases. A new class of molecules, live biotherapeutics, will also be introduced. Finally, tert-butyl alcohol will be reintroduced. This co-solvent eases the process of freeze-drying and was in the spotlight twenty years ago. Today, an application in the biologics field will be presented.

9:15 The European F-Gas Regulation and the Consequences for Pharmaceutical Freeze-Drying

Thomas Beutler, *GEA Lyophil*

9:45 Freeze Dryer Refrigeration System

Alexander Tambovzev, *OPTIMA*

10:15 Tert-Butyl Alcohol as an Excipient in Freeze-Drying of a Monoclonal Antibody

Julian Gitter, *LMU Munich*

10:45 Coffee Break, Poster Session & Exhibition

11:15 Freeze-Drying of a New Class of Medicines: Live Biotherapeutics

Sophie Declomesnil, *4DPharma*

11:45 Development of a Freeze-Dried Antigen-Expressing Adenoviral Vector Platform

Frederic Mathot, *GSK Vaccines*
Erwan Bourles, *GSK*

12:15 Q&A, Discussion

12:45 Lunch Break, Poster Session & Exhibition

Session 2 Equipment Characterization

Moderator: **Thomas Beutler**, *GEA Lyophil*

Defining the important parameters to characterize a freeze-dryer can result in a quite complex scenario. Some characteristics impact drying and quality, others less or not at all. Defining the characteristics of a freeze-dryer by looking at square meters, cooling, or vacuum performance is certainly not enough. The complexity is much higher and the data which could potentially be used for scale-up and transfer may be inadequate or not comparable between different types of systems. Many users have therefore developed their own methods of characterizing their equipment to achieve comparability. The aim of this session is to share some of these methods and to let us learn from each other.

13:45	Opportunities of Using Mass Spectrometer Technology in Lyophilization	Johannes Meiwald, <i>Pfeiffer Vacuum</i>
14:15	Lyophilizer Characterization: Determination of Equipment Heat and Mass Transfer Properties to Support Scale-up and Technical Transfer of Lyophilized Biopharmaceuticals	Sean Cullen, <i>Sanofi</i>
14:45	Use of Water Sublimation Test for Freeze-Dryer Cycle Adjustment to Avoid Meltback of a Low Cake Weight Lyo Product	Eric Miguez, <i>Universal Farma</i>
15:15	Q&A, Discussion	
15:30	Coffee Break, Poster Session & Exhibition	

Session 3 Critical Quality Attribute Monitoring

Moderator: **Julian Gitter**,
University of Munich

Control and assessment of relevant critical product quality attributes are vital for good manufacturing practice and process understanding. During this session, a focus will be placed on the advantages of non-destructive moisture determination of freeze-dried products for 100% batch control, moisture shelf mapping, equipment characterization and even for lyophilization cycle development. Moreover, a case study will show the power of a simple model for the prediction of vial fogging occurrence in lyophilized products based on different primary packaging materials and formulations.

16:00	Fast NIR Sensor for Online Moisture Control	Axel Haefner, <i>GEA Lyophil</i>
16:30	Statistical Confidence in the Process: Insights Gained using Non-Destructive Moisture Determination Methods	Derek Duncan, <i>LIGHTHOUSE Instruments</i>
17:00	Methods to Predict Fogging in Lyophilized Drug Products	Cristina Grigore, <i>DPS Lonza</i>
17:30	Panel Discussion, Q&A	
18:00	End of Conference Day 1	
18:30	Networking Event (For details, see ad on page 10)	

Wednesday, 28 November 2018

Session 4 QbD Considerations

Moderator: **Raf De Dier**, Janssen J&J

'Quality by Design' has become a topic of routine discussion in the pharmaceutical industry. However, many are finding it difficult to implement this abstract concept into the daily production area and struggle in providing confidence that quality indeed is designed in the process - and risk is reduced. In this session, we will go beyond the basic principles of QbD serving those who require a more integrated approach to this initiative. Focus will be placed on reports of implementation and case studies using sensors and models, in a way to provide a control strategy to provide quality and robustness within the lyophilization process.

9:00	Lyophilization Validation - Thermal Mapping	Davide Postacchini, <i>Kaye</i>
-------------	--	---------------------------------

9:20	Another View of Freeze Dryer Design Space	Alexander Tambovzev, <i>Optima Pharma</i>
-------------	--	---

9:40	Recent Experiences with Continued Process Verification of a Lyocycle - Product Temperature as Process Control	Andrea Weiland-Waibel, <i>Explicat Pharma</i>
-------------	--	---

10:00	Q&A, Discussion	
--------------	----------------------------	--

10:30	Coffee Break, Poster Session & Exhibition	
--------------	--	--

Session 5 New Technologies & Container Systems

Moderator: **Joerg Luemkemann**, Roche

Freeze-drying in the pharmaceutical environment has mainly been performed in the final container in recent decades. An advantage is the superior aseptic handling of the product, but thermodynamic issues of freeze-drying are especially supported by glass vials, for example. Furthermore, therapeutic modalities like devices, advanced primary containers (DCS, etc.) appear on the market and offer significant benefit both for patients and care-givers. This session will elucidate alternatives to freeze-drying in vials.

11:00	Optimization of Freeze Drying Nanocapsules by Using Experimental Design	Ghania Hamdi-Degobert, <i>University of Lyon</i>
--------------	--	--

11:30	Novel Approach to Drug Delivery: Spray Freeze-Dried Particles	Alf Lamprecht, <i>University of Bonn</i>
--------------	--	--

12:00	Freeze Drying in Novel Container Platforms	Daniel Kullmann, <i>Hoffmann-La Roche</i>
--------------	---	---

12:30	Q&A, Discussion	
--------------	----------------------------	--

13:00	Lunch Break, Poster Session & Exhibition	
--------------	---	--

Session 6 Predictive Models in Freeze Drying

Moderator: **Yves Mayeresse**, GSK

Sascha Pfeiffer,
Lyo Engineering

There's a trend in the industry for in silico modelling of pharmaceutical processes. Going by trial and error is time consuming. Scale-up and product transfer equally represent huge investments in terms of time to market and asset mobilization. In this session, new tools to gather information on the process will be introduced, and new model approaches mixing experiment and theoretical calculation will be discussed. In the second part, the importance of product collapse for pharmaceutical applications will be reviewed. Finally, a closing discussion will allow us to revisit all the subjects that have been discussed during the previous two days. It's the perfect opportunity for comments and sharing ideas, and it will be a good place to ask any burning question still pending.

14:00	Process Modelling in Combination with Experimental Model Parameter Determination	Leon Klepzig, Technical University Clausthal
14:30	Process Parameter Determination by Through Vial Impedance Spectroscopy: A Prediction of Ice Interface Temperatures and Single-vial Heat Transfer Coefficients	Geoff Smith, De Montfort University
15:00	Coffee Break, Poster Session & Exhibition	
15:30	Collapsed Lyophilized Drug Product - A Case Study	Daniel Molnar, Boehringer Ingelheim
	Closing Panel Discussion, Q&A <ul style="list-style-type: none"> • Revision of Annex 1 • Frequency of Steam Sterilization for FDs • Media Simulation Duration • Any other pressing issues 	
16:30	End of Conference & Farewell	



FLOOR PLAN



Exhibitor	Table Top
4tune Engineering	14
Biopharma	20
Christ	16
Grupo Alava	9
Hof	11
Indatech	10
LIGHTHOUSE	8

Exhibitor	Table Top
Lyo-Engeneering	19
OMPI	13
Pfeiffer-Vacuum	15
Tempris	12
Wilco	18

TO EXHIBIT:

PDA meetings and conferences are a great opportunity for your company to gain on-site exposure in front of highly-qualified, upper-level professionals in the pharmaceutical and biopharmaceutical industry. Exhibition and Sponsorship Opportunities are available. A basic exhibition package for this event is priced **1.895 Euro net (table-top)**. For more information please contact gomez@pda.org



“No me ha dejado”

SEVILLE

“NO8DO” is the official motto of Seville. It is popularly believed to be a rebus signifying the Spanish “No me ha dejado”, meaning “It [Seville] has not abandoned me”. The eight in the middle represents a madeja or skein of wool. Legend states that the title was given by King Alfonso X, who was resident in the city’s Alcázar and supported by the citizens when his son, later Sancho IV of Castille, tried to usurp the throne from him. The emblem is present on the municipal flag and features on city property such as manhole covers, and Christopher Columbus’s tomb in the Cathedral.

Source: Wikipedia

NO8DO

Training & Education Program

europe.pda.org



PDA Education offers courses that are developed and taught by experts. They are uniquely targeted to professionals involved in the development and manufacturing of quality pharmaceutical and biopharmaceutical products.

Facts that Make a Difference

- Up-to date training courses and workshops taught by internationally renowned experts
- Wide range of training courses with hands-on experience to drive expertise, awareness, and innovation
- Customized in-house training courses and workshops available



PDA Education Program

29 November 2018

**Application of a Risk-Based Approach
to Freeze-Drying Processes**

One-Day Training Course

29-30 November 2018

**Development of a
Freeze-Drying Process**

Two-Day Training Course

29-30 November 2018

**CMC Regulatory Compliance for
Biopharmaceuticals**

Two-Day Training Course

29-30 November 2018

Extractables & Leachables

Two-Day Training Course

Application of a Risk-Based Approach to Freeze-Drying Processes

Overview

One masterpiece of current process validation approach is risk analysis. It allows defining and measuring the critical parameters of the process for which a specific level of scrutiny is necessary in order to end-up with a robust process under control. The objective of this course is to give an understanding of risk management through ICHQ9 applied to the Freeze-Drying process. The first part will review the guidelines, the Freeze-Drying process and the tools available to score the risks. The second part will be fully interactive. Participants will express their views in terms of detectability, occurrence and control of the various risks linked to the Freeze-Drying process. The session will be subdivided into different chapters: Product, Process, Critical Quality Attributes, Ancillary Function of the equipment and Aseptic Level. The different tools to perform risk analysis will be described and the main focus will be on an FMEA (Failure Mode and Effects Analysis) approach. The output of the workshop is a table consisting of the different parameters with their associated level of criticality that will be shared with the participant.

Who Should Attend:

This course is designed specifically for people having an interest in Freeze-Drying. The audience can come from the various horizons of people performing technical risk assessment, including, but not limited to: production, quality assurance, validation, engineering and development specialist.

Learning Objectives:

Upon completion of this course, you will be able to:

- Better understand the Freeze-Drying process explained through the different examples
- Master ICH Q9 approach in term of risk-based approach
- Recognize a critical parameters for a process
- Score the criticality of a parameters
- Work in team by reaching consensus around criticality levels



Yves Mayeresse, *GlaxoSmithKline Vaccines*

Yves Mayeresse is director in manufacturing technology inside MSAT by GlaxoSmithKline Vaccines. He has more than twenty years of experience in the pharmaceutical sector and has worked for different companies. Yves has managed activities such as parenteral production, set-up of new Freeze-Drying facilities, design of Freeze-Drying cycle and development of new stabilizers for freeze-dried products. Transfer of product towards different internal and external site. He has worked on the industrialization of new freeze-dried products and then in the technical life cycle management. Now, Yves is focusing on different technologies used for the primary and secondary operations. He is an engineer in biochemistry, has written articles about Freeze-Drying science and is a regular speaker for conferences on Freeze-Drying. Since 2016 he is the Leader of the PDA Interest Group Lyophilization and coordinates the group's activities in Europe.

Thursday, 29 November 2018
9:00 – 17:00

- 9:00 Theoretical Part**
- ▶ *Brief review of ICH Q9*
 - ▶ *Description of Freeze-Drying Technology*
 - The equipment
 - The process
 - The product and the primary packaging items
 - The ancillary function (SIP, CIP)
 - Aseptic level (automatic loading, people presence)
 - ▶ *Tools Presentation*
 - Input / Output parameters
 - Dependent / Independent parameters
 - CQA: Critical Quality Attributes
 - FMEA approach
 - Examples

10:30 Coffee Break

- 11:00 Practical Part**
- ▶ *Team rule and organization*
 - ▶ *Part I: Product*
 - Independent parameters linked to formulation
 - Independent parameters linked to freeze-dryer load
 - ▶ *Part II: Process*
 - Independent parameters linked to the freeze-dryer

12:30 Lunch Break

- 13:30 Practical Part**
- ▶ *Part II (continued): Process*
 - Independent parameters that are measured and controlled during the cycle
 - Dependent parameters linked to the Freeze-Drying cycle
 - ▶ *Part III: Critical attributes linked to Freeze-Drying process*
 - ▶ *Part IV: Ancillary Function*
 - SIP

15:15 Coffee Break

- 15:45 Practical Part**
- ▶ *Part IV (continued): Ancillary Function*
 - CIP
 - ▶ *Part V: Aseptic Level*

- 16:30 Conclusions**
- ▶ *Q&A*
 - ▶ *Feedback about the approach*

17:00 End of Training Course

Development of a Freeze-Drying Process

Bring your own samples
for discussion

Overview

This workshop will give a thorough introduction into the Physics and Thermodynamics of Freeze-Drying. This seminar comes with an additional overview about technical aspects to be considered and gives an overview about current technologies available on the market. It is created to introduce all people who are professionally linked to Freeze-Drying and might be of special interest for cycle developers (R&D), upscale & transfer specialists, project managers & engineers, process & site engineers, qualification & validation specialists. Open problem examination allows you to bring in a current problem linked to Freeze-Drying. The group will discuss and evaluate possible approaches for troubleshooting.

Who Should Attend:

This course is designed specifically for

- Cycle Developers (R&D)
- Upscale & Transfer Specialists
- Project Managers & Engineers
- Process & Site Engineers
- Qualification & Validation Specialists
- Members of Parenteral Production Teams

Learning Objectives:

Upon completion of this course participants will know the basic principles of all Freeze Drying aspects:

- Physical / Thermodynamic Theory of Nucleation, Sublimation and Desorption
- Technical & Technological Solutions to accomplish a standard process
- Based on the prior theory, several hands-on-sessions provide practical knowledge to design a Freeze-Drying process
- Basics of qualification of a freeze dryer



Georg Frinke, *Bayer Pharma*

Georg holds a degree in Engineering from UAS, Cologne, Germany. He is Process Engineer at Bayer Pharma and responsible for the technical operation of the parenteral facility. Previously, he worked as Process Engineer for Optima (Klee) and GEA Lyophil / Steris. Among others, he is specialized in the development of customized Freeze-Drying processes (particularly upscaling with PAT) and in the qualification (FAT, SAT, IQ, OQ, PQ) of pharmaceutical freeze dryers.

Thursday, 29 November 2018 9:00 – 18:30

THEORY

9:00 Introduction

- Introduction to Drying Technologies
- Overview of the Freeze Drying Process
- Properties of Water
- Properties of Heat Transfer during Lyophilization

10:00 Nucleation (with Parallel Hands-on)

- Scientific Basics
- Freezing Process
- Sensors & PAT

11:00 Coffee Break

11:30 Nucleation (Cont.)

- Hands-on: Freezing of Sucrose in a Lyo with integrated thermo-resistant measurement

12:45 Lunch Break

13:45 Sublimation

- Scientific Basics
- Drying Process
- Sensors & PAT
- Hands-on: Ice-temperature calculation based on manometric temperature measurement

16:00 Coffee Break

16:30 Desorption

- Scientific Basics
- Residual Moisture
- Sensors & PAT
- Hands-on: Preparation and start of a lyo-process

Bring in your Questions:
Real problems of Freeze Drying can be presented and will be discussed in the group

18:30 End of Day 1

Friday, 30 November 2018 8:30 – 17:00

TECHNOLOGIES & PRACTICE

8:30 Repetition of Previous Day Theory

9:00 Hands-On: Recipe Development

11:00 Coffee Break

11:30 Process Design

- Derive design requirements from process requirements
- Process requirements
 - Process steps of Lyo-cycle
 - Auxiliary processes for parenteral production

12:30 Lunch Break

13:30 Design of a Lyophilizer - From Engineering to Qualification

- Vessel system
 - Shelf system
 - chamber system
 - condenser system)
- CIP / SIP-Equipment
- Qualification procedures
 - CIP-Process
 - SIP-Process
 - Leak Test

15:30 Auxiliary Systems of a Lyophilizer

- Aeration System with Filter test
- Sensor Equipment / PAT Methods
- Vacuum System
- Heat Transfer System
- Refrigeration System

15:00 Coffee Break

16:30 Hands-on:

- Evaluation of the Lyo experiment & samples of collapsed probe

17:00 End of Training Course

CMC Regulatory Compliance for Biopharmaceuticals

Overview

Biopharmaceuticals (i.e., biological medicines sourced from genetically-engineered living systems) for treatment of human diseases have become a significant percentage of the pharmaceutical industry. And not just the recombinant DNA-derived proteins and monoclonal antibodies (both from the innovators and biosimilars); but now, an increasing awareness of the importance of gene therapy and genetically engineered cellular medicinal products.

These biopharmaceuticals are being developed by many companies whose Chemistry, Manufacturing & Control (CMC) teams have varying degrees of familiarity or experience with the regulatory requirements for these challenging products. Companies clearly understand the critical importance of their human clinical study strategy, but frequently, the development of a strategy for CMC is an afterthought. Add the frequent lack of CMC regulatory compliance experience in some companies, coupled with the complexity of the biological manufacturing processes and products, and this can be a recipe for disaster.

This course will provide insights and practical guidance for the CMC teams to develop an acceptable cost-effective, risk-based CMC regulatory compliance strategy for biopharmaceuticals (recombinant proteins, monoclonal antibodies, genetically engineered viruses and human cells) from early clinical stage development through market approval. The course emphasis will include FDA, EMA and ICH guidance.

Who Should Attend:

This course is designed specifically for those involved in or interested in the manufacture and control and CMC regulatory issues of biopharmaceuticals, including Senior Management, Directors and Managers/Supervisors, QA/QC, Regulatory Affairs, Manufacturing and Process Development personnel.

Learning Objectives:

Upon completion of this course, you will be able to:

- Explain the importance and underlying principles of an effective CMC regulatory strategy for biopharmaceuticals to move your products through clinical development into the marketplace
- Explain the importance and underlying principles for CMC regulatory compliance of biopharmaceuticals and how this leads regulatory agencies to have different CMC regulatory requirements for biotech products compared to pharmaceuticals of chemical origin.



John Geigert, PhD, BioPharmaceutical Quality

John Geigert is President of BioPharmaceutical Quality Solutions, which for the last 15 years has specialized in providing CMC regulatory strategy consulting for the biopharmaceutical industry. He has over 40 years of CMC industrial experience and leadership in the biopharmaceutical industry. He has held senior management positions as Vice President of Quality at both IDEC Pharmaceuticals Corporation in San Diego and Immunex Corporation in Seattle, and he was Director of Product Development at Cetus Corporation in Berkeley.

At these companies, he helped lead the CMC efforts to obtain regulatory approvals for 6 biopharmaceutical products now commercially available in the U.S. and in Europe. John Geigert has served on the PDA Board of Directors, currently chairs the PDA Biopharmaceutical Advisory Board, and has served as an expert member of the USP Biotechnology Committee. He is the author of the book *The Challenge of CMC Regulatory Compliance for Biopharmaceuticals and Other Biologics 2nd Edition*, and has written extensively for RAPS Focus (What Senior Management Needs to Know About CMC Regulatory Compliance for Biotech Products (Aug-Nov 2009, 4-part series)), *Demystifying CMC Regulatory Strategy* (Sept 2011-Mar 2012, 4-part series). John Geigert obtained his B.S. in Chemistry from Washington State University and his Ph.D. degree in Organic/Analytical Chemistry from Colorado State University.

Thursday, 29 November 2018

9:00 – 17:00

9:00 Welcome and Introduction

CMC Regulatory Challenges for Biopharmaceuticals are Different

9:10 – Painting the Terminology Landscape: Biologic, specified biologic, biopharmaceutical, biosimilar, CBER, CDER, EMA, ...

10:30 Coffee Break

11:00 – Understanding the CMC Differences of Biopharmaceutical Regulation between FDA and EMA
– Biopharmaceuticals are not Chemical Drugs – Regulatory Compliance Consequences of the four Major CMC Differences

12:30 Lunch Break

How to Develop an Effective Corporate CMC Risk-Managed Control Strategy for Biopharmaceuticals

13:30 – Three Major Forces that Shape the CMC Regulatory Compliance Strategy of all Biopharmaceuticals
– Five Key Elements of an Effective Corporate CMC Regulatory Compliant Strategy

15:00 Coffee Break

15:30 – Impact of the Quality by Design (QbD) on Biopharmaceutical CMC Strategy
– Necessity of a Clinical Phase - Appropriate CMC Regulatory Compliance Strategy

17:00 End of Day 1

Friday, 30 November 2018

9:00 – 17:00

Applying a CMC Risk-Managed Control Strategy to the Biopharmaceutical Manufacturing Process

09:00 – Four Myths about Biopharmaceutical Starting Material – the Master Cell Bank
– Necessity of Confirming Clonality and Genetic Stability

10:30 Coffee Break

– Importance and Limitations of small-scale Studies for Biopharmaceuticals

– Clinical Phase - Appropriate Control of the Biopharmaceutical Manufacturing Process

– Formulation and Container-Closure Challenges for Biopharmaceuticals – Impact of Components on the Biopharmaceutical (e.g., protein aggregation) and Impact of the Biopharmaceutical on Components (e.g. glass delamination)

12:30 Lunch Break

Challenge of Managing Manufacturing Process Changes and Demonstrating Biologic Product Comparability – Not an Easy Task!

13:30 – Need for Risk-based, Sequential and Clinical Phase - Appropriate Comparability Studies
– Demonstrating Biologic Product Comparability – Justifying CMC Differences

15:00 Coffee Break

15:30 – “Comparability Protocol” and “Post Approval Change Management Protocol”

– Extreme Comparability of Biosimilars:
Limitations of CMC Comparison, Fingerprinting – CMC Biosimilarity Successes and Failures

17:00 End of Training Course

Extractables & Leachables

Including: Important Regulatory Updates – Case Study Section: Selection of the most interesting Case Studies, presented over the last 10 years!

Overview

When making Parenteral Drug Products, pharmaceutical companies are faced with the need to further investigate the materials that will be in contact with the drug product, either during manufacturing, intermediate storage, storage in its final packaging, or during the delivery of the drug to the patient. While historically, the potential safety issues were the main driver in these kinds of investigations, recently, also quality issues – i.e. for biopharmaceuticals – have become an additional concern. This workshop will look at “Extractables & Leachables” from many different angles: Definitions, Regulatory, Material & Polymer Science, Analytical E/L Methodologies, Safety Assessments, Study Design for different parenteral primary packaging systems, as well as for injection devices.

Learning Objectives

Upon completion of this workshop, you will be able to:

- Explain in detail the current regulatory requirements for container/closure qualification from an E/L perspective.
- Explain the upcoming changes in regulations, standards and recommendations from PQRI, USP and BPOG and how these changes could impact a future evaluation of a pharmaceutical C/C-system.
- Understand the materials of construction – and their composition – of container closure systems, and how they could impact the safety and quality of a parenteral drug product.
- Put together an evaluation program (review of provided documentation, analytical testing) of different types of parenteral drug product container/closure systems.
- Perform a safety/risk assessment of analytical results, obtained after completion of an E/L study.

Who Should Attend

- Pharmaceutical Packaging and Device Engineers
- Production Engineers, using SU systems
- Regulatory Affairs Officers
- Pharmaceutical R & D Managers
- Analytical Chemists, working on E/L
- Quality Assurance Officers



Dennis Jenke, PhD, Chief Executive Scientist, Triad Scientific Solutions

Dennis Jenke is the Chief Executive Scientist for Triad Scientific Solutions, a provider of science-based solutions to plastic/product compatibility challenges associated with packaging, manufacturing equipment and delivery devices in the pharmaceutical, cosmetic, food and related industries. He was a Distinguished Scientist at Baxter Healthcare Corporation where for more than three decades he lead a team whose primary responsibility includes the assessment of material/product compatibility, specifically with respect to establishing the suitability for use of packaging systems, manufacturing systems and administration devices for pharmaceutical products (for example, extractables/leachables and product ingredient binding). He has published extensively in the areas of analytical chemistry, environmental science and material/solution compatibility and serves as an expert reviewer for numerous pharmaceutical and analytical journals. He is the author of the book *Compatibility of Pharmaceutical Solutions and Contact Materials; Safety Considerations Associated with Extractables and Leachables* and a contributing author to the *Leachables and Extractables Handbook*. Dennis Jenke is a member of numerous industry groups whose charter is to establish best demonstrated practices in the area of material/solution compatibility.

Thursday, 29 November 2018

9:00 – 18:00

Introduction on Extractables & Leachables (E/L)

- ▶ What is the importance of a good E/L-qualification
- ▶ Historical cases of leachables, impacting the quality or the safety of a drug product
- ▶ Regulatory requirements (FDA, EMA...) for primary packaging

Understanding the Materials, Used in the Manufacture of Pharmaceutical Containers & Closures

- ▶ Types of polymers – examples in medical/pharmaceutical use
- ▶ Understanding the composition of polymers
- ▶ The issues with glass in parenteral applications

FULL Session on Updates of E/L- Regulations, Standards and Recommendations

- ▶ Pharma Packaging:
 - Preview of the final PQRI Parenteral Drug Product (DPD) & ODP Chemistry group
 - Update on the most recent developments on the USP <661> chapters
- ▶ Devices
 - Chemical characterization of devices according to ISO 10993-18: What changes are coming up?
 - Upcoming Revisions of the USP <87> and USP <88>: Where could it go to?
- ▶ (Bio)Pharmaceutical Manufacturing
 - Where is USP with the update on the USP <661.3> Plastic Manufacturing Components standard

How to Perform a Safety Evaluation – Risk Assessment on Extractables & Leachables

- ▶ Toxicology 101
- ▶ EMA Guideline on Genotoxic Impurities
- ▶ ICH M7 (DNA reactive Impurities) and its suggested staged approach
- ▶ The Threshold Concept of PQRI (OINDP and PDP/ODP)
- ▶ Examples

How to Look at Injection Devices from an E/L Perspective

- ▶ Medical device regulations versus pharma packaging
- ▶ Test selection process for devices: What to do?
- ▶ USP and ISO 10993 series for biocompatibility testing
- ▶ Case: Injection device



Piet Christiaens, PhD, Scientific Director, Nelson Labs NV

Piet Christiaens received his Ph.D. from the Analytical Chemistry Department of the University of Leuven (Belgium) in 1991. From 1992 to 1997, he was Lab Manager in two Analytical Contract Laboratories. From 1997 to 2000, he worked as an independent consultant with Shell Chemical Company in Houston, Texas where he conducted research on a new hydrogenation catalyst system for Hydrogenated Triblock Co-Polymers (Kraton Polymers). Since 2001, Mr. Christiaens has been Scientific Director developing analytical methods and protocols for both extractables and leachables studies for the Medical and Pharmaceutical Industries. Mr. Christiaens oversees all laboratory operations at Nelson Labs Europe and supports the European business development team.

Friday, 30 November 2018**9:00 – 16:30****E/L Testing for Small Volume Parenteral Applications**

- ▶ Glass Syringes: the issues with tungsten, glue residues and silicone oil and glass metals leaching
- ▶ The Issue with rubbers: the plunger, the needle shield or the tip cap: different approaches needed?
- ▶ The impact of secondary packaging – option or necessity?
- ▶ Setting up extractable & leachable studies for a pre-filled Syringe or a vial system

E/L Testing for Lyophilized Drug Products

- ▶ Primary packaging for the lyophilized drug product – modus of interaction with the DP
- ▶ Impact of the “21CFR Part 4” on combination products, used in the administration of a lyo DP
- ▶ Critical aspects when designing leachable studies for lyophilized DP
- ▶ Integration of the administration procedure (e.g. IV-set, pump system) in leachables evaluation

Large Volume Parenterals

- ▶ The challenge in E/L testing for LVP's
- ▶ Primary packaging for LVP's – critical materials and components
- ▶ Secondary packaging for LVP: critical points to consider

E/L Testing for Disposable and Single-Use Systems in Bioproduction

- ▶ How to classify the risk of different single-use systems in the bioproduction process
- ▶ Understanding BPSA & BPOG recommendations, and how they can be implemented in the study design
- ▶ Performing E/L studies on filters: potential approaches

Analytical Techniques and Methodologies in E/L Research

- ▶ Discussion of the Analytical Instrumentation used
- ▶ The Analytical Chromatographic Screening Process to Discover, Identify and Quantify Organic Extractables
- ▶ The Risk of Omissions with the Screening Process
- ▶ The Risk of Inexact Identifications in the Screening Process
- ▶ The Risk of Inaccurate Quantification when Screening
- ▶ A Risk Mitigation Strategy when Implementing a Screening Methodology

How to Set-up Extractables & Leachables Studies

- ▶ Selecting the right conditions for extraction
- ▶ How to select the right compounds to monitor in a leachable study
- ▶ Designing a leachable study

**John Iannone**, *Principal Consultant, iCG Solutions*

John Iannone has a background in Biomedical Engineering from Boston University. Since joining the Biotech/ Medtech Industry 15 years ago, John has assisted multiple pharmaceutical & medical device companies with the development of their product safety evaluation strategies. Currently he is a Principal Consultant for iCG, LLC. His areas of expertise include Material Qualification & Biocompatibility, Extractables & Leachables, Chemical Characterization, and attainment of Biological or Toxicological risk assessments for medical devices, pharmaceutical container systems, bioprocessing systems, and combination products. John has given numerous technical presentations and has led many workshops on Extractable & Leachable Considerations, Biocompatibility, Microbiology, and Regulatory Testing Requirements. He also participates in the development of both industry groups' recommendations and regulatory guidelines through Expert Panel membership, global Technical Committees, and industry collaborations.

VENUE**Meliá Sevilla**

Calle Dr. Pedro de Castro 1
41004 Seville
Spain
<https://goo.gl/z6qeem>

Housing at the selected hotel will be in high demand, so we strongly recommend making your reservations early.

DIRECTIONS

© Google For directions click on the picture, scan the QR-code or go to <https://goo.gl/maps/asRQwUszrqv>

CONTACT INFORMATION**Conference Inquiries****Melanie Decker**

Director Events & Exhibitions
decker@pda.org

Conference Program Inquiries**Sylvia Becker, Teresa Schubach**

programs-europe@pda.org

Registration Customer Care

Tel: +49 30 436 55 08-10
registration-europe@pda.org

Education Program Inquiries**Elke von Laufenberg**

training-europe@pda.org

Exhibition / Sponsorship Inquiries**Nadjeschda Gomez-Stahl**

gomez@pda.org

GENERAL ADDRESS

PDA Europe gGmbH
Am Borsigturm 60
13507 Berlin, Germany
Tel: +49 30 436 55 08-0
Fax: +49 30 436 55 08-66

TO EXHIBIT:

Exhibition and Sponsorship Opportunities are available. PDA meetings and conferences are a great opportunity for your company to gain on-site exposure in front of highly-qualified, upper-level professionals in the pharmaceutical and biopharmaceutical industry. Exhibit at PDA events and let your company's products or services become a valuable tool or resource for our attendees.

SPECIAL REQUIREMENTS

If you require special accommodations to fully participate, please attach a written description of your needs with your registration form. Specific questions can be directed to registration-europe@pda.org.

**Lufthansa****Austrian****brussels airlines****Eurowings****SWISS****Special offer: Discounted travel with Lufthansa Group Airlines**

Lufthansa Group Partner Airlines offer a comprehensive global route network linking major cities around the world. We offer special prices and conditions to participants, visitors, exhibitors, invited guests as well as employees of the Contracting partner and their travel companions. To make a reservation, please click on **www.lh.com/event-flight-booking** and enter the access code **DEZJESQ** in the "Access to Your Special Lufthansa Offer" area. This will open an online booking platform that will automatically calculate the discount offered or provide you with an even better offer if another promotional fare is available.

NOTE: Pop-ups must be enabled otherwise the booking platform window will not open.

These promotional fares are also available through your IATA / ARC travel agent. Travel agents can obtain ticketing instructions by sending an email to **lufthansa.mobility@dlh.de** and providing the access code as a reference.

27-28 November 2018 | Seville | Spain

This PDF-file provides an automatic fill-in function. Your signature, however, is needed in writing.

Your registration is only complete upon filling in and submitting both pages of this form.

1 Registration

A 200€ late fee will apply for conference registrations after 23 November 2018

All fees given in Euro, excluding VAT (21 %)

27-28 November Conferences

☐ **Pharmaceutical Freeze Drying Technology**

☐ **11th Workshop on Monoclonal Antibodies**

As part of the PDA Exchange meeting format, you can attend the two meetings with just one ticket

Conferences Fee

PDA Member ☐ **1595** **Nonmember ☐ **1895** **Regulatory/Academic ☐ **800**

☐ **Poster Presenter please mark here** (written approval required, conference fee applies)

29 November

One-Day Training Course

Training Course Fee

Application of a Risk-Based Approach to Freeze-Drying Processes

All Participants ☐ **845**

29-30 November

Two-Day Training Course

Training Course Fee

Development of a Freeze Drying Process

All Participants ☐ **1495**

29-30 November

Two-Day Training Course

Training Course Fee

CMC Regulatory Compliance for Biopharmaceuticals

All Participants ☐ **1495**

29-30 November

Two-Day Training Course

Training Course Fee

Extractables and Leachables

All Participants ☐ **1495**

Your consent is important. We manage your personal data responsibly.

For more information, please visit pda.org/privacy-policy

RESPONSE REQUIRED – By checking the box(es) below, I consent to:

- ☐ My contact information (name, company, job title, city, state, country) being printed on the attendee list distributed at the event.
- ☐ PDA recording and / or photographing me and using those recordings and / or photographs in future PDA promotional and marketing materials.*
- ☐ PDA sending me promotional information via email.
- ☐ PDA sending me promotional information via post.

* This consent refers to the use of footage and pictures linked to your name, for example giving a testimonial for the event and publishing your picture and your name. For your information, general pictures of the event for documentation and promotion purposes might be taken, but no names will be published.

The fee includes course documentation as well as mid-session refreshments and lunch. Excellent networking opportunities with snacks and drinks will be given. The fee does not include the hotel accommodation. PDA Europe has secured a limited number of rooms at a special group rate.

****Registration fee includes a one-year PDA membership** if no further special discount is granted. If you do not wish to join PDA and receive the benefits of membership, please check here (same rate applies). ☐

Group Registration Discount Register 5 colleagues for the conference at the same time and receive the **5th registration free**. For more information on group discounts please contact Antje Petzholdt at petzholdt@pda.org. Other discounts cannot be applied..

☐ **Discount for Exhibiting Companies**

Please mark here if your company is an exhibitor to this event and you will receive the conference ticket at the **special price of 1095 € per ticket**. No further discounts are applicable with this option (as PDA Membership Discount or Group Ticket discount).

This PDF-file provides an automatic fill-in function. Your signature, however, is needed in writing.

27-28 November 2018 | Seville | Spain

3 WAYS TO REGISTER

- 1 **ONLINE:** pda.org/EU/MABS2018
 2 **FAX:** +49 30 4365508-66
 3 **EMAIL:** registration-europe@pda.org

2 Your Contact Information

If this form is an update to a previously submitted form, please check here. ☐

☐ Mr.

☐ Ms.

☐ Dr.

☐ Nonmember

☐

I want to become a PDA Member.
Please send me a subscription form

☐ PDA Member

☐ ID Number

Name (Last, First, MI)

Job Title

Company

Department

Mailing Address

City

Postal Code

Country

Email

Business Phone

Fax

☐ Substituting for

(Check only if you are substituting for a previously enrolled colleague; a nonmember substituting for member must pay the membership fee.)

3 Information about Visa Matters

- All registrations which will involve visa matters will have to be submitted to PDA EU four weeks prior to the start of the event at the latest. For later registrations, PDA Europe will be unable to assist participants in any visa affairs.
- All costs incurring in connection with visa affairs shall be borne by registrants. (This applies in particular to costs for submitting documents by courier.)
- Potential participants must be clients of UPS shipping agency and submit their UPS customer reference number to PDA EU (together with their registration).

4 Payment Options

☐ **By Bank Transfer**

Beneficiary: PDA Europe gGmbH
IBAN: DE73 1007 0024 0922 8735 00
BIC (SWIFT-Code): DEUTDE33HAN
Bank Address:

Deutsche Bank, Welfenallee 3-7,
 D-13465 Berlin, Germany

☐ **By Credit Card**

☐ American Express ☐ MasterCard ☐ VISA

For your credit card information safety:
Please send your details by fax only.

☐ **Purchase Order**

Purchase Order Number

Billing Address: ☐ Same as contact information address above.

If not, please send your billing address to: petzholdt@pda.org

**Your Company
 VAT I.D.:**

This number starts by your country code with two characters
 (example: PDA Europe's country code starts with: DE | followed by the number)

PDA Europe VAT I.D.: DE254459362

**Your registration is only complete upon filling in
 and submitting both pages of this form.**

Date

Mandatory Signature

CONFIRMATION: Transmitting your filled-in registration form constitutes a binding application for the specific event. PDA Europe will send you a confirmation including payment details. **A legally binding contract is concluded once PDA Europe has sent a written invoice by mail to you.** A letter of confirmation will be sent to you within one week once payment has been received. You must have this written confirmation to be considered enrolled for this PDA event. PDA Europe reserves the right to deny access to anyone unable to provide written confirmation that all dues have been fully settled. **SUBSTITUTIONS:** If you are unable to attend, substitutions are welcome and can be made at any time, including on site at the prevailing rate. If you are registering as a substitute attendee, please indicate this on the registration form. Changes are free of charge until 2 weeks prior to the start of the event. After this two-weeks period, there will be a charge of € 100 per name change. **REFUNDS: Refund requests must be sent to PDA Europe.** If your written request is received on or before **14 October 2018**, you will receive a full refund minus a 150 € excl. VAT handling fee. After that time, no refund or credit requests will be approved. If you are an unpaid registrant and do not attend the event, you are responsible for paying the registration fee. On-site registrants are not guaranteed to receive conference materials until all advanced registered attendees receive them. PDA Europe works PCI-Compliant. **EVENT CANCELLATION:** PDA reserves the right to modify the material or speakers/instructors without notice, or to cancel an event. If an event must be canceled, registrants will be notified by PDA as soon as possible and will receive a full refund. PDA will not be responsible for airfare penalties or other costs incurred due to cancellation. For more details, contact PDA at info-europe@pda.org or fax to +49 30 4365508-66.

2018 PDA EUROPE EVENTS

22 November	Project Management in the Pharmaceutical Industry	★ Berlin, Germany
27-28 November	Pharmaceutical Freeze Drying Technology	★ Seville, Spain
27-28 November	11 th Workshop on Monoclonal Antibodies	★ Seville, Spain
11 December	Annex 1 Workshop	Berlin, Germany

2019 PDA EUROPE EVENTS

19-20 March	Parenteral Packaging	★ Venice, Italy
16-17 May	Pharmacopoeia	★ Geneva, Switzerland
4-5 June	Advanced Therapy Medicinal Products	★ Vilnius, Lithuania
25-26 June	4 th PDA Europe Annual Meeting	★ Amsterdam, The Netherlands
3-4 September	BioManufacturing	★ Berlin, Germany
24-25 September	Pharmaceutical Freeze Drying Technology	★ Berlin, Germany
24-25 September	Particles in Injectables	★ Berlin, Germany
8 October	Project Management in the Pharmaceutical Industry	★ Berlin, Germany
22-23 October	The Universe of Pre-filled Syringes and Injection Devices	★ Gothenburg, Sweden

Subject to change

For latest info: europe.pda.org

Shortlist 16 Nov 2018

★ Events with additional Education Program. More information – europe.pda.org



Connecting People, Science and Regulation®

General Information
PDA Europe gGmbH
Am Borsigturm 60
13507 Berlin, Germany
Tel: +49 30 4365508-0
Fax: +49 30 4365508-66



europe.pda.org